We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Stimulating Thyrotropin Receptor Antibodies Amplify Fibroblast Expression of TSH and IGF-1 Receptors: Insights into Thyroid Eye Disease Pathogenesis

MedXY Editorial Team•Jul 1, 2026•Diabetes & Endocrinology
autoantibodiesfibroblastsIGF-1 receptorThyroid Eye DiseaseThyrotropin receptor

Highlight

Stimulating thyrotropin receptor antibodies (TSHR antibodies) upregulate both TSHR and insulin-like growth factor-1 receptor (IGF-1R) expression on fibroblasts, key players in thyroid eye disease (TED). This effect is mediated primarily through receptor recycling rather than increased gene transcription and can be inhibited by blocking endocytosis, unveiling potential therapeutic avenues.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

β-Cell Dysfunction Enhances Prediction of Type 1 Diabetes Progression in Individuals with Single Autoantibody PositivityAssessment of β-cell dysfunction using stimulated glucose and C-peptide measures improves risk stratification for type 1 diabetes progression among single autoantibody-positive relatives, enabling personalized monitoring and targeted intervSep 15, 2026Why Metrics Matter in Thyroid Eye Disease: Exploring the Innovate TED InitiativeThis article examines the critical need for refined clinical metrics in thyroid eye disease (TED) to better evaluate new targeted therapies, highlighting the Innovate TED Initiative’s efforts to develop and validate comprehensive outcome meSep 13, 2026Satralizumab Demonstrates Promising Efficacy and Safety in Treating Thyroid Eye Disease: Insights from Phase 3 SatraGO-1 and SatraGO-2 TrialsPhase 3 trials show satralizumab significantly improves proptosis, inflammation, and diplopia in thyroid eye disease with a favorable safety profile, marking a new therapeutic option targeting the IL-6 receptor pathway.Sep 12, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Autoantibody Screening in Sibling-Dominant Pediatric Relatives of Type 1 Diabetes Patients: Prevalence, Determinants, and Psychological Impact
This multicentre Turkish study identifies ZnT8 autoantibodies as predominant in young siblings at risk for type 1 diabetes and highlights gestational age as a protective factor, while revealing significant anxiety changes in children and pa
Sep 6, 2026
Fibroblast-Derived Spondin-2: A Key Driver of Metaplasia-to-Dysplasia Progression in Gastric EpitheliumThis study identifies fibroblast-secreted Spondin-2 as a crucial mediator promoting the transition from metaplastic to dysplastic gastric epithelial cells, advancing understanding of early gastric carcinogenesis.Aug 28, 2026
Teprotumumab Versus Intravenous Glucocorticoids in Thyroid Eye Disease: Insights from a Japanese MRI StudyThis study evaluates teprotumumab’s effectiveness for thyroid eye disease in Japanese patients, revealing notable improvements in orbital inflammation and proptosis compared to intravenous glucocorticoid therapy with distinct MRI-baseAug 26, 2026